Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Effects of Three Years Treatment With Once-Yearly Zoledronic Acid on the Kinetics of Bone Matrix Maturation in Osteoporotic Patients

Gamsjaeger, Sonja, Hofstetter, B, Zwettler, Elisabeth, Recker, Robert, Gasser, Juerg Andreas, Eriksen, Erik Fink, Klaushofer, Klaus and Paschalis, Eleftherios P (2012) Effects of Three Years Treatment With Once-Yearly Zoledronic Acid on the Kinetics of Bone Matrix Maturation in Osteoporotic Patients. Osteoporosis International.


INTRODUCTION: Yearly 5-mg infusions of Zolendronic acid (ZOL) for 3 years have shown pronounced antifracture efficacy. The purpose of the present study was to test whether ZOL affects the kinetics of forming bone material properties maturation.
METHODS: Iliac crest biopsies obtained during the HORIZON-PFT clinical trial were analysed by Raman microspectroscopy in the area of actively bone forming surfaces as a function of tissue age (ZOL = 23, placebo (PLC) = 47)) in trabecular and osteonal bone, to determine ZOL’s effect on bone material quality indices (mineral / matrix, relative proteoglycan content, mineral crystallinity) maturation kinetics.
RESULTS: Mineral / matrix ratio increased in both groups as a function of tissue age, at both osteonal and trabecular bone forming surfaces, ZOL exhibiting the greatest increase in the trabecular surfaces only. The relative proteoglycan content showed a dependency on tissue age in both trabecular and osteonal surfaces, with the ZOL receiving patients exhibiting significantly lower values in the tissue age 8-22 days in the trabecular surfaces. Mineral crystallinity (both crystallite length and thickness) showed a dependence on tissue age, with ZOL-treated patients exhibiting lower crystallite length compared to PLC only in the 8-22 day old tissue at trabecular surfaces, while crystal thickness was lower in the 1-5 day old tissue at both osteonal and trabecular surfaces.
CONCLUSIONS: The results of the present study suggest that once-yearly administration of intravenous ZOL for 3 years in humans does not exert any deleterious effects on the evolution of intrinsic bone material properties at actively forming osteonal and trabecular surfaces, while it may have a beneficial effect on the progression of the mineral to matrix ratio and mineral maturity / crystallinity bone quality indices.

Item Type: Article
Additional Information: The manuscript provides an extension of the data analysis which was published previously: Gamsjaeger S, Buchinger B, Zwettler E, Recker R, Black D, Gasser JA, Eriksen EF, Klaushofer K, Paschalis EP 2010 Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly zoledronic acid. J Bone Miner Res. (JBMR 2010 Jul 19. [Epub ahead of print])
Keywords: bisphosphonate, bone maturation, osteoporosis, zoledronic acid, Raman spectroscopy
Date Deposited: 02 May 2016 23:45
Last Modified: 02 May 2016 23:45